Search form

NHF thanks its sponsor Baxter

Hemophilia Pharmacy Management

NHF thanks its sponsor Baxter

NHF thanks its sponsor Baxter

NHF thanks its sponsor CSL Behring

NHF thanks its sponsor CSL Behring

NHF thanks its sponsor CSL Behring

NHF thanks its sponsor CSL Behring

NHF thanks its sponsor CSL Behring

NHF thanks its sponsor CSL Behring

NHF thanks its sponsor Grifols

NHF Hemophilia Walk

Hemophilia Pharmacy Management

NHF thanks its sponsor Baxter

MASAC Recommendation Regarding Factor Concentrate Prescriptions and Formulary Development and Restrictions

PrintFriendly

Printer Friendly and PDF

MASAC Recommendation: 159

MASAC Recommendation Regarding Factor Concentrate Prescriptions and Formulary Development and Restrictions

Date: 
March 12, 2005
AttachmentSize
MASAC Document286.79 KB
  • Persons with bleeding disorders require treatment with clotting factor concentrates for prevention and treatment of bleeding.

    Clotting factor therapies are neither pharmacologically nor therapeutically equivalent and vary based upon purity, half-life, recovery, method of manufacture, viral removal & inactivation processes, potential immunogenicity, and other attributes. The characteristics of each product and the resultant product choice for an individual patient require a complex decision making process with the ultimate product being agreed upon by the patient and their respective healthcare provider. It is critical that the bleeding disorder community has access to a diverse range of therapies and that prescriptions for specific clotting factor concentrates are respected and reimbursed.

    MASAC supports continued availability and reimbursement of the full range of all prescribed replacement therapies for treatment of bleeding disorders. Prescriptions for clotting factor therapies should be written as non-generic to assure that the product prescribed is appropriately dispensed and reimbursed. Reimbursement for clotting factor replacement therapies should continue to be based upon methodologies appropriate to each specific product. The benefit of limiting products to one within a class, such as one recombinant factor VIII concentrate, solely for the purpose of cost containment is not supported by present clinical practice or by published data.